(Q43834221)

27 November 2017

0 references

Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

Fausto Petrelli

1

1 reference

27 November 2017

Karen Borgonovo

2

1 reference

27 November 2017

Mary Cabiddu

3

1 reference

27 November 2017

Mara Ghilardi

4

1 reference

27 November 2017

Sandro Barni

5

1 reference

27 November 2017

publication date

1 February 2011

1 reference

International Journal of Colorectal Disease

27 November 2017

published in

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

7

1 reference

27 November 2017

page(s)

823-833

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1149-0

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

21 January 2018

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

1 reference

12 December 2020

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

1 reference

12 December 2020

10.1007/S00384-011-1149-0

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

1039158304

0 references

1 reference